164 related articles for article (PubMed ID: 38158767)
1. Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer.
Zhang Q; Guo F; Liu H; Hong L
Int Wound J; 2024 Apr; 21(4):e14569. PubMed ID: 38158767
[TBL] [Abstract][Full Text] [Related]
2. miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β-catenin signaling and autophagy via targeting HMGA2.
Song Z; Liao C; Yao L; Xu X; Shen X; Tian S; Wang S; Xing F
Cancer Gene Ther; 2023 Apr; 30(4):596-607. PubMed ID: 36494581
[TBL] [Abstract][Full Text] [Related]
3. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
Wang G; Li L; Li Y; Zhang LH
Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.
Cai Y; An B; Yao D; Zhou H; Zhu J
Bioengineered; 2021 Dec; 12(2):10713-10722. PubMed ID: 34747309
[TBL] [Abstract][Full Text] [Related]
5. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
6. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
Cai L; Zhang Q; Du L; Zheng F
Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
[TBL] [Abstract][Full Text] [Related]
7. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
[TBL] [Abstract][Full Text] [Related]
9. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1.
Zhang XL; Sun BL; Tian SX; Li L; Zhao YC; Shi PP
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3635-3644. PubMed ID: 31114988
[TBL] [Abstract][Full Text] [Related]
11. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
Gao Y; Huang Y
J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
13. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
14. Circ_0026123 promotes cisplatin resistance and progression of ovarian cancer by upregulating RAB1A through sequestering miR-543.
Wei L; He W; Zhao H; Zhao P
Anticancer Drugs; 2022 Nov; 33(10):1069-1080. PubMed ID: 36255068
[TBL] [Abstract][Full Text] [Related]
15. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
16. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer.
Han X; Liu D; Zhou Y; Wang L; Hou H; Chen H; Zhang L; Chen W; Li X; Zhao L
Cell Biol Int; 2021 Jan; 45(1):227-237. PubMed ID: 33090550
[TBL] [Abstract][Full Text] [Related]
17. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
18. Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer.
Yin Y; Li J; Rong J; Zhang B; Wang X; Han H
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):261-274. PubMed ID: 35179434
[TBL] [Abstract][Full Text] [Related]
19. Baohuoside I inhibits resistance to cisplatin in ovarian cancer cells by suppressing autophagy via downregulating HIF-1α/ATG5 axis.
Zhou Y; Liu T; Wu Q; Wang H; Sun Y
Mol Carcinog; 2023 Oct; 62(10):1474-1486. PubMed ID: 37283234
[TBL] [Abstract][Full Text] [Related]
20. FTX Regulated miR-153-3p/FOXR2 to Promote Cisplatin Resistance in Ovarian Cancer.
Liu M; Peng J
Comput Math Methods Med; 2022; 2022():2318170. PubMed ID: 35651928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
